![Zai Qi Wang](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Zai Qi Wang
Directeur Général chez InxMed Biotechnology Nanjing Co., Ltd.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Fei Cao | M | - |
InxMed Biotechnology Nanjing Co., Ltd.
![]() InxMed Biotechnology Nanjing Co., Ltd. BiotechnologyHealth Technology InxMed Biotechnology Nanjing Co., Ltd. is a clinical-stage biotech company established in 2018, dedicated to developing innovative therapies to overcome treatment resistance, especially anti PD-1/PD-L1 resistance. InxMed is based in Nanjing, China, and has teams located in Shanghai and Beijing, with hubs in San Francisco and Melbourne. The Chinese company's innovations are inspired by patients and driven by in-depth understanding of disease biology and pharmacology. InxMed has raised tens of millions of US dollars in series A round financing and has an integrated high-caliber research and clinical development team across China, the US, and Australia. The company has built a unique innovative pipeline through its own discovery research and development and collaborative research and development. The company was founded in 2018 by Fei Cao and Zai Qi Wang, with Zai Qi Wang serving as the CEO since then. | 6 ans |
Michael Keyoung | M | 50 |
InxMed Biotechnology Nanjing Co., Ltd.
![]() InxMed Biotechnology Nanjing Co., Ltd. BiotechnologyHealth Technology InxMed Biotechnology Nanjing Co., Ltd. is a clinical-stage biotech company established in 2018, dedicated to developing innovative therapies to overcome treatment resistance, especially anti PD-1/PD-L1 resistance. InxMed is based in Nanjing, China, and has teams located in Shanghai and Beijing, with hubs in San Francisco and Melbourne. The Chinese company's innovations are inspired by patients and driven by in-depth understanding of disease biology and pharmacology. InxMed has raised tens of millions of US dollars in series A round financing and has an integrated high-caliber research and clinical development team across China, the US, and Australia. The company has built a unique innovative pipeline through its own discovery research and development and collaborative research and development. The company was founded in 2018 by Fei Cao and Zai Qi Wang, with Zai Qi Wang serving as the CEO since then. | 4 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Statistiques
Pays | Relations | % du total |
---|---|---|
Chine | 2 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Zai Qi Wang
- Réseau Personnel